Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 21:5:59.
doi: 10.1186/s40064-016-1700-0. eCollection 2016.

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life

Ornella Garrone  1 , Filippo Montemurro  2 , Chiara Saggia  3 , Nicla La Verde  4 , Anna Maria Vandone  1 , Mario Airoldi  5 , Enrico De Conciliis  6 , Michela Donadio  7 , Francesco Lucio  8 , Maria Antonia Polimeni  9 , Maria Vittoria Oletti  10 , Alice Giacobino  11 , Marco Carlo Merlano  1
Affiliations

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life

Ornella Garrone et al. Springerplus. .

Abstract

This retrospective multicenter analysis was aimed to evaluate clinical activity and tolerability of eribulin in pretreated metastatic breast cancer patients in clinical practice. Patients treated with eribulin from January 2012 to July 2013 were enrolled in the observational study from 10 italian hospitals. Tumor and toxicity evaluation were performed according to Agenzia Italiana Farmaco. One-hundred and thirteen patients were included in the study. Median age 62 years old. 71.7 % of the patients had visceral involvement and the majority had a burden of disease involving two or more organs with a median number of 2 (1-6). The median number of previous chemotherapy regimens for advanced disease was 3 (1-10). Median number of eribulin cycles was 4 (1-27). Overall response rate was 24 % (95 % CI 16.0-31.8). Clinical benefit rate, was 35.4 % (95 % CI 26.6-44.2). At a median follow-up of 29.6 months (8.3-41.9) the median progression free survival was 3.3 months (0.6-26.7; 95 % CI 2.4-4.2), and the median overall survival 11.6 months (0.6-33.3; 95 % CI 8.7-14.5). No correlation was recorded between subtypes in terms of ORR and CBR. Toxicity was manageable. Main common grade 3-4 toxicities were neutropenia (19.4 %), febrile neutropenia (0.9 %), asthenia (3.5 %), abnormal liver function test (1.8 %), stomatitis (0.9 %). Our results confirm that treatment with eribulin is feasible and safe in real-world patients.

Keywords: Eribulin; Metastatic breast cancer; Real life; Toxicity.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Progression free survival
Fig. 2
Fig. 2
Overall survival
See this image and copyright information in PMC

References

    1. Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2012;23(6):1441–1448. doi: 10.1093/annonc/mdr444. - DOI - PubMed
    1. Cardoso F, Costa A, Norton L, Senkus E, AaproM André F, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) Breast. 2014;23:489–502. doi: 10.1016/j.breast.2014.08.009. - DOI - PubMed
    1. Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. JCO. 2010;28(25):3922–3928. doi: 10.1200/JCO.2009.25.8467. - DOI - PubMed
    1. Cortes J, O’Shaughnessy J, Loesh D, Blum JL, Vadhat LT, Petrakova K, et al. On behalf of the Embrace (Eisai Metastatic Breast Cancer Assessing Physician’s Choice Versus E7389) investigators. Lancet. 2011;377:914–923. doi: 10.1016/S0140-6736(11)60070-6. - DOI - PubMed
    1. Dabydeen DA, Burnett JC, Bai R, Verdier-Pinard P, Hickford SJ, Pettit GR, et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol. 2006;70(6):1866–1875. doi: 10.1124/mol.106.026641. - DOI - PubMed

LinkOut - more resources